Aveanna Healthcare (AVAH) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
20 Mar, 2026Strategic vision and leadership
Focus on transforming homecare value through a diversified, national platform serving pediatric, adult, and geriatric patients in 38 states.
Leadership team with deep industry experience, including CEO, CFO, and Principal Accounting Officer with backgrounds in operations, finance, and accounting.
Financial performance and growth
2026 revenue guidance of $2.54–$2.56 billion, with a 9.3% CAGR from 2020–2026 and adjusted EBITDA guidance of $318–$322 million.
Q4 2025 revenue grew 27.4% year-over-year to $662.5 million, with adjusted EBITDA up 54% to $85 million.
Free cash flow for 2025 was $131 million, with operating cash flow of $125.9 million.
Liquidity of $528.8 million and total variable rate debt of $1.49 billion, supported by interest rate hedges.
Business segments and operational highlights
Three main segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS).
PDS: $2.0 billion revenue, 257 locations, 42,600 patients, 26–28% gross margin, 3–5% organic growth.
HHH: $249 million revenue, 82 locations, 14,800 patients, 50–52% gross margin, 5–7% organic growth.
MS: $184 million revenue, 30,700 patients, 42–44% gross margin, 8–10% organic growth.
Latest events from Aveanna Healthcare
- Double-digit revenue and profit growth in 2025, robust 2026 outlook, major acquisition announced.AVAH
Q4 202519 Mar 2026 - Q2 revenue up 7% to $505M, adjusted EBITDA up 27%, guidance raised despite lower net income.AVAH
Q2 20242 Feb 2026 - Strategic transformation and rate wins drive growth, staffing, and margin expansion in 2024.AVAH
Healthcare Services Conference1 Feb 2026 - Accelerating growth via preferred payer strategy, targeting $200M EBITDA by 2026.AVAH
Jefferies Global Healthcare Conference1 Feb 2026 - 2025 guidance raised as transformation and Q3 results drive scalable, value-based growth.AVAH
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Q3 revenue up 6.5%, adjusted EBITDA rose 32.2%, and guidance was raised for 2024.AVAH
Q3 202416 Jan 2026 - Strategic transformation and efficiency drive growth, margin expansion, and strong cash flow.AVAH
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Strong 2024 revenue and margin gains, with 2025 guidance signaling further growth.AVAH
Q4 202424 Dec 2025 - Registering $400M in securities and 54M+ shares for resale, targeting home care growth.AVAH
Registration Filing16 Dec 2025